Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xenon Pharmaceuticals Inc. - Common Shares
(NQ:
XENE
)
44.64
-0.20 (-0.45%)
Streaming Delayed Price
Updated: 10:27 AM EST, Dec 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Xenon Pharmaceuticals Inc. - Common Shares
< Previous
1
2
3
4
5
Next >
Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology
December 26, 2025
As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine...
Via
PredictStreet
Topics
Economy
Intellectual Property
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares
↗
December 08, 2025
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares
Via
The Motley Fool
Topics
Regulatory Compliance
Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock
↗
December 03, 2025
One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear.
Via
The Motley Fool
Topics
Initial Public Offering
Regulatory Compliance
Earnings Scheduled For November 3, 2025
↗
November 03, 2025
Via
Benzinga
A Look Ahead: Xenon Pharmaceuticals's Earnings Forecast
↗
August 08, 2025
Via
Benzinga
Earnings Scheduled For May 12, 2025
↗
May 12, 2025
Via
Benzinga
What to Expect from Xenon Pharmaceuticals's Earnings
↗
May 09, 2025
Via
Benzinga
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?
↗
December 03, 2025
One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years.
Via
The Motley Fool
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet?
↗
December 03, 2025
Soleno just turned profitable for the first time—right as a major fund made its move.
Via
The Motley Fool
Topics
Regulatory Compliance
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance?
↗
December 03, 2025
One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.
Via
The Motley Fool
Topics
Regulatory Compliance
Earnings Scheduled For February 27, 2025
↗
February 27, 2025
Via
Benzinga
Earnings Scheduled For November 12, 2024
↗
November 12, 2024
Via
Benzinga
Earnings Preview: Xenon Pharmaceuticals
↗
November 11, 2024
Via
Benzinga
Earnings Scheduled For February 29, 2024
↗
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Earnings Outlook For Xenon Pharmaceuticals
↗
February 28, 2024
Via
Benzinga
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away
↗
December 03, 2025
This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.
Via
The Motley Fool
Topics
Regulatory Compliance
Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors
↗
December 03, 2025
One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.
Via
The Motley Fool
Topics
Regulatory Compliance
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares
↗
December 03, 2025
Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?
Via
The Motley Fool
Topics
Regulatory Compliance
4 Analysts Have This to Say About Xenon Pharmaceuticals
↗
December 08, 2023
Via
Benzinga
These stocks are moving in today's after hours session
↗
November 03, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
Insights into Xenon Pharmaceuticals's Upcoming Earnings
↗
October 31, 2025
Via
Benzinga
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit
↗
July 07, 2025
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.
Via
Stocktwits
Crude Oil Gains 3%; US Inflation Eases In April
↗
May 13, 2025
Via
Benzinga
Topics
Economy
Earnings Scheduled For August 11, 2025
↗
August 11, 2025
Via
Benzinga
This Discover Financial Services Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
↗
May 07, 2025
Via
Benzinga
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
↗
May 07, 2025
Via
Benzinga
XENE Stock Earnings: Xenon Pharmaceuticals Misses EPS for Q2 2024
↗
August 08, 2024
XENE stock results show that Xenon Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
XENE Stock Earnings: Xenon Pharmaceuticals Beats EPS for Q1 2024
↗
May 09, 2024
XENE stock results show that Xenon Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
↗
February 21, 2024
Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials.
Via
InvestorPlace
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
↗
February 16, 2024
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
